Drug General Information (ID: DDI6XJ2N7E)
Drug Name			Lepirudin		Drug Info		Vorapaxar		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antithrombotic Agents				Antiplatelet Agents/Protease-Activated Receptor-1 Antagonists
Structure

Mechanism of Lepirudin-Vorapaxar Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Lepirudin				Vorapaxar
Mechanism		Risk of bleeding Anticoagulant				Risk of bleeding Antiplatelet
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Lepirudin and Vorapaxar

Recommended Action
Management		Concomitant use of vorapaxar with warfarin or other anticoagulants should generally be avoided.

References
1	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.